Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Apr 2009
Case ReportsGenetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
Somatic epidermal growth factor receptor (EGFR) mutations in exons 19 and 21 have been found in non-small cell lung cancer (NSCLC) and are associated with the therapeutic response to gefitinib in patients with advanced NSCLC. We report a case of pleomorphic carcinoma of the lung with different EGFR mutations. Prior to gefitinib treatment, an exon 19 deletion of EGFR mutation was positive in the specimens obtained from pleural effusion and left cervical lymph node, histologically proven to be adenocarcinoma. ⋯ Although the adenocarcinomatous tissue was still positive for exon 19 deletion of EGFR mutation alone, sarcomatous components had both the exons 19 deletion and 20 T790M mutation concomitantly, thought to be a gefitinib resistance mutation. Pulmonary pleomorphic carcinoma is a rare NSCLC composed of biphasic and heterogeneous malignant cell populations. The present case suggested that expression of different EGFR mutations is related to the biphasic histological appearance in pulmonary pleomorphic carcinoma.
-
Jpn. J. Clin. Oncol. · Mar 2009
Etiologies of delirium and their relationship to reversibility and motor subtype in cancer patients.
Delirium is one of the most commonly encountered complications in patients with cancer. The etiology of delirium in cancer is often multi-factorial, and few reports have examined the causes of delirium. This study investigated the causes of delirium and their association with reversibility and motor subtypes of delirium in cancer patients. ⋯ When treating delirium, prevalences of the causes of delirium, as identified in this study, should be kept in mind. Further research is required to investigate what specific treatments may facilitate the prompt recovery from delirium among cancer patients.
-
Jpn. J. Clin. Oncol. · Mar 2009
Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.
With regard to adjuvant chemotherapy for non-small-cell lung cancer, the usefulness of combined chemotherapy with cisplatin (CDDP) and vinorelbine (VNR) has been reported. However, poor compliance has been reported with VNR administered weekly by the conventional method for 16 consecutive weeks, and there is no report on the safety and compliance of adjuvant chemotherapy with CDDP and VNR in Japanese patients. ⋯ This study was retrospective and had some limitations, for example, non-hematological toxicity would be evaluated milder. However, it was considered that adjuvant chemotherapy with CDDP administered on Day 1 and VNR administered on Days 1 and 8 every 3 weeks was safe, and that the rate of completion of the four cycles was also satisfactory in Japanese patients.
-
Jpn. J. Clin. Oncol. · Feb 2009
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy. ⋯ Ramosetron proved to be an effective alternative for the control of CRINV during upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy.
-
Jpn. J. Clin. Oncol. · Dec 2008
Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma: treatment outcome and prognostic factors.
To evaluate the treatment outcome of patients with locally recurrent nasopharyngeal carcinoma (NPC) treated with re-irradiation and chemotherapy. ⋯ Age and stage at recurrence were identified as prognostic factors for OS and PFS. Patients received external beam radiation therapy at a total dose of more than 110 Gy should be careful for severe late toxicities, and it is thought to be the optimal dose for recurrent tumor.